Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hongjun Li
Institutions:
Second Hospital of Tianjin Medical University,
Jining Medical University
Observed institutions:
Second Hospital of Tianjin Medical University,
Jining Medical University
ORCID:
0009-0002-1784-3605
Observed ORCID:
0009-0002-1784-3605
OpenAlex ID:
A5036684906
Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
·
Clinical Cancer Research
·
12
PDF
Circ_0128846/miR-140-3p/JAK2 Network in Osteoarthritis Development
2021
·
Hongjun Li
, Zhongyu Liu
, et al.
·
Immunological Investigations
·
10
Case Report: A case of interstitial pneumonia in a colorectal cancer patient with a history of lung cancer treated with cetuximab
2025
·
Yang Yang
, Bin Zhang
, et al.
·
Frontiers in Oncology
·
2
PDF
Data from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Table S1 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S5 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S2 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S3 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Figure S1 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Table S4 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Figure S2 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Effect of Danhong injection on expression of nephrin and podocin in podocyte of renal tissue in rats with membranous nephropathy
2019
·
Xiaoyun Guo
, Hongjun Li
, et al.
·
Traditional Chinese Medicine
Show more works
View as search
Works count:
12
Citation count:
24
H-index:
2
I10-index:
2
Year
Topic
Type